MAPT and COVID-19: Post-COVID-19 neurological symptomatology was associated with higher plasmatic levels of SARS-CoV-2 antibodies and elevated plasmatic biomarkers of neuronal dysfunction (amyloid-beta, light neurofilament, neurogranin, tau, and phosphorylated (p-T181-tau)) [16,49,50].